Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can fixing abnormal brain vessels help the brain clear its waste?

NCT ID NCT07824297

Knowledge-focused Sponsor: Hospital Universitari Vall d'Hebron Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are studying whether abnormal connections between arteries and veins in the brain's covering, called intracranial dural arteriovenous fistulae, affect the brain's waste-clearance system, known as the glymphatic system. About 20 adults who are already scheduled for standard endovascular embolization to treat these fistulae will have advanced brain MRI scans before treatment and again about six months later. The team will compare imaging markers of glymphatic function before and after the procedure to explore whether treatment is associated with changes in these markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study finds a link, it could help doctors understand whether treating these abnormal vessel connections also improves the brain's waste-clearance system, which may matter for thinking and memory.
What could go wrong
This is a small observational study of 20 people, so it cannot prove cause and effect. MRI markers of glymphatic function are still experimental, and any changes seen after treatment may have other explanations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with angiographically confirmed diagnosis of unruputred intracranial dAVFs, aged 18-99 years, candidate for endovascular embolization treatment with curative intent.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 to 99 years. * Angiographically confirmed diagnosis of unruptured intracranial dAVF. * Candidate for endovascular embolization treatment with curative intent. * Able to undergo Brain MRI. Exclusion Criteria: * Contraindication to angiographic embolization procedures. * Acute intracranial haemorrhage secondary to dAVFs rupture and/or venous hypertension. * Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study, other contraindications to MRI such as certain metallic implants.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dural arteriovenous fistula are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Central Nervous System Vascular Malformations dural sinus malformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dural arteriovenous fistula Glymphatic system

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario Vall D'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • University of Oxford

    NOT_YET_RECRUITING

    Oxford, OX3 9DU, United Kingdom

  • Università di Bologna

    NOT_YET_RECRUITING

    Bologna, 40127, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.